![]() Lacidipine-13C8 structure
|
Common Name | Lacidipine-13C8 | ||
---|---|---|---|---|
CAS Number | 1261432-01-2 | Molecular Weight | 463.48 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C1813C8H33NO6 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Lacidipine-13C8Lacidipine-13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3]. |
Name | Lacidipine-13C8 |
---|
Description | Lacidipine-13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3]. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Molecular Formula | C1813C8H33NO6 |
---|---|
Molecular Weight | 463.48 |